<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458445</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-311</org_study_id>
    <nct_id>NCT00458445</nct_id>
  </id_info>
  <brief_title>A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators</brief_title>
  <official_title>A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether SPD465 is safe and effective in the&#xD;
      treatment of ADHD in young adult drivers after a duration of 16 hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study was stopped by the sponsor before enrollment based on a non-safety related corporate&#xD;
    decision.&#xD;
  </why_stopped>
  <start_date type="Actual">April 30, 2007</start_date>
  <completion_date type="Actual">June 15, 2007</completion_date>
  <primary_completion_date type="Actual">June 15, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Simulated Driver Safety (DS) Score averaged over 3 driving assessments at one interim and one final visit.</measure>
    <time_frame>Interim visit = Week 3; Final visit = Week 7.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interim &amp; final visits: Attention-Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV)</measure>
    <time_frame>Interim visit = Week 3; Final visit = Week 7.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interim &amp; final visits: Clinical Global Impressions of Improvement (CGI-I)</measure>
    <time_frame>Interim visit = Week 3; Final visit = Week 7.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interim &amp; final visits: Self-Rating of Simulated Driver Safety (DS) Performance Questionnaire</measure>
    <time_frame>Post DS Testing - Interim visit = Week 3; Post DS Testing - Final visit = Week 7.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>SPD465 then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then SPD465</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD465</intervention_name>
    <arm_group_label>Placebo then SPD465</arm_group_label>
    <arm_group_label>SPD465 then Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a material that may look similar to SPD465, however, contains no active drug.</description>
    <arm_group_label>Placebo then SPD465</arm_group_label>
    <arm_group_label>SPD465 then Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must have a valid driver's license with a minimum of 3 years of driving&#xD;
             experience.&#xD;
&#xD;
          2. Subject reports daily driving activity.&#xD;
&#xD;
          3. Subject is fluent in English.&#xD;
&#xD;
          4. Subject must be male or non-pregnant, non-lactating female who agrees to comply with&#xD;
             any applicable contraceptive requirements of the protocol.&#xD;
&#xD;
          5. Subject must have a satisfactory medical assessment with no clinically significant or&#xD;
             relevant abnormalities&#xD;
&#xD;
          6. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD) established by a&#xD;
             comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject is significantly underweight or morbidly obese.&#xD;
&#xD;
          2. Subject has a controlled (requiring a restricted medication) or uncontrolled, comorbid&#xD;
             psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder&#xD;
             (PTSD), psychosis, bipolar illness, severe obsessive compulsive disorder, severe&#xD;
             depressive or severe anxiety disorder or other symptomatic manifestations that, in the&#xD;
             opinion of the examining Physician, will contraindicate SPD465 treatment or confound&#xD;
             efficacy or safety assessments.&#xD;
&#xD;
          3. Subject with a lifetime history of psychosis or bipolar disorder.&#xD;
&#xD;
          4. Subject with any concurrent chronic or acute illness or unstable medical condition,&#xD;
             either treated or untreated.&#xD;
&#xD;
          5. Subject with a history of mental retardation or a severe learning disability.&#xD;
&#xD;
          6. Subject is na√Øve to ADHD treatment with methylphenidate or amphetamine.&#xD;
&#xD;
          7. Subject has a history of glaucoma or narrow angle glaucoma.&#xD;
&#xD;
          8. Subject has a history of seizure (other than infantile febrile seizures), any tic&#xD;
             disorder, or a current diagnosis and/or family history of Tourette's Disorder.&#xD;
&#xD;
          9. Subject has known cardiac structural abnormalities as well as any other condition that&#xD;
             may affect cardiac performance.&#xD;
&#xD;
         10. Subject has clinically significant ECG or laboratory abnormalities at Screening or&#xD;
             Baseline.&#xD;
&#xD;
         11. Subject has a history of hypertension or has a resting sitting systolic blood pressure&#xD;
             &gt;139mmHg or diastolic blood pressure &gt;89mmHg10.&#xD;
&#xD;
         12. Subject has used any psychoactive prescription medication or over-the-counter (OTC)&#xD;
             medication requiring more than a 28-day washout. Hormonal contraceptives are&#xD;
             acceptable.&#xD;
&#xD;
         13. Subject has a documented allergy, intolerance, or documented history of&#xD;
             non-responsivity to amphetamine.&#xD;
&#xD;
         14. Subject currently has (or had a history within the last 6 months) a substance use&#xD;
             disorder (excluding nicotine).&#xD;
&#xD;
         15. Subject has taken another investigational drug or taken part in a clinical trial&#xD;
             within the last 30 days prior to Screening.&#xD;
&#xD;
         16. Female subject is pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Attention-Deficit Hyperactivity Disorder (ADHD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

